Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Ablasser, K; Verheyen, N; Glantschnig, T; Agnetti, G; Rainer, PP.
Unfolding Cardiac Amyloidosis -From Pathophysiology to Cure.
Curr Med Chem. 2019; 26(16):2865-2878
Doi: 10.2174/0929867325666180104153338
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Ablasser Klemens
- Rainer Peter
- Co-Autor*innen der Med Uni Graz
- Glantschnig Theresa
- Verheyen Nicolas Dominik
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Deposition of amyloidogenic proteins leading to the formation of amyloid fibrils in the myocardium causes cardiac amyloidosis. Although any form of systemic amyloidosis can affect the heart, light-chain (AL) or transthyretin amyloidosis (ATTR) account for the majority of diagnosed cardiac amyloid deposition. The extent of cardiac disease independently predicts mortality. Thus, the reversal of arrest of adverse cardiac remodeling is the target of current therapies. Here, we provide a condensed overview on the pathophysiology of AL and ATTR cardiac amyloidoses and describe treatments that are currently used or investigated in clinical or preclinical trials. We also briefly discuss acquired amyloid deposition in cardiovascular disease other than AL or ATTR. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
- Find related publications in this database (Keywords)
- Amyloidosis
- heart failure
- pre-amyloid oligomers
- fibrils
- immunoglobulin light chains
- transthyretin
- desmin
- posttranslational modification